Antagonism of tumour necrosis factor α in refractory asthma

Mike A Berry,1 Ian D Pavord2

Asthma that is refractory to treatment with inhaled corticosteroids affects 5–10% of patients with asthma; it is an important health and economic problem in the UK and most industrialised nations. It is estimated that €17.7 billion is spent on asthma healthcare per annum in Europe,1 of which a disproportionately large amount is attributed to patients with refractory asthma, on average six times more per patient compared with mild to moderate disease.2 Patients with this condition suffer considerable morbidity and mortality and they therefore represent an important unmet clinical need. The European Respiratory Society3 and the American Thoracic Society4 have identified research into the mechanisms and treatment of refractory asthma as a research priority.

Asthma can be apparently refractory to treatment because of poor treatment adherence or because symptoms are caused by comorbid conditions such as rhinitis, hyperventilation and bronchiectasis.4 However, a significant number of patients have genuinely severe disease. The patterns of refractory disease are heterogeneous, both between and within patients: some have recurrent exacerbations with satisfactory day-to-day control of symptoms and lung function; in others the predominant feature is symptoms due to persistent airway dysfunction. There is also heterogeneity in the response to treatment, with some patients not achieving control despite maximum corticosteroid therapy and others achieving control, but requiring an unacceptably high dose systemic corticosteroid treatment to do so. We are only beginning to understand how these different clinical patterns of disease relate to airway dysfunction and the pattern of airway inflammation. The ultimate hope is that better understanding of refractory asthma phenotypes might allow additional treatment to be better targeted. This is important, as treatment options are often expensive and potentially toxic. Until treatment can be targeted effectively and consistently across multiple sites, we should be prepared for the frustrating roller coaster of initial encouraging results from single centre studies of small numbers of well characterised patients followed by disappointing results from larger multicentre studies. The anti-tumour necrosis factor α (TNFα) story in refractory asthma is a good example of this.

The rationale for investigating the role of TNFα in refractory asthma is strong. Firstly, many of the pathophysiological abnormalities that set refractory asthma apart from more easily controllable disease, including increased neutrophilic airway inflammation, exaggerated airway remodelling, corticosteroid resistance, fixed airflow obstruction and systemic inflammation, can be explained on the basis of increased TNFα production within the airway.1–3 Secondly, factors associated with the development of refractory asthma such as smoking,7 endotoxin exposure,8 obesity9 and chronic infection10 are associated with activation of the innate immune response and therefore might be expected to increase airway TNFα production. Thirdly, there is consistent evidence that TNFα is overexpressed in refractory asthma compared with mild to moderate asthma, not only within the airway11 but also systemically.12 Fourthly, administration of inhaled recombinant TNFα leads to airway hyperresponsiveness in patients with asthma13 and in normal controls,14 possibly via a direct effect on airway smooth muscle15 or associated mast cells.16 The final impetus for investigating the TNFα axis in refractory asthma is that it has become practical to do so with the advent of a number of antagonists, which have been shown to be effective and reasonably safe in other diseases associated with TNFα overproduction.

Initial experience with anti-TNFα treatment of refractory asthma was very encouraging. In an initial open label, 12 week study17 and a subsequent 10 week double blind, randomised, placebo controlled, crossover study of 10 subjects,18 treatment with etanercept was associated with a marked reduction in methacholine airway responsiveness, improved symptoms, better quality of life scores and improved lung function. The findings in less severe asthma have been less compelling. In a double blind, placebo controlled, parallel group design study of 38 patients, treatment with infliximab for 12 weeks resulted in a decrease in the number of patients with mild deteriorations in asthma control compared with placebo, but there was no effect on the primary endpoint, change in morning peak expiratory flow.19 No major safety issues were raised in the three studies and there was considerable enthusiasm to extend this work to multicentre studies of larger populations employing more patient relevant outcomes.

One such study is reported by Morjaria and colleagues20 in this issue of Thorax (see page 584). They carried out a randomised, placebo controlled, parallel group study of 12 weeks of treatment with etanercept in 39 subjects with refractory asthma. Treatment was associated with a significant reduction in the Juniper Asthma Control Score, reflecting better asthma control, but no significant effect on asthma related quality of life. There was no effect of treatment on airway responsiveness or lung function nor was there a clinically important effect on measures of eosinophilic and neutrophilic airway inflammation.

Why are the findings of this study so much less compelling than the findings of the initial pilot studies? The population studied by Morjaria and colleagues20 had much less severe airway hyperresponsiveness than the population studied in the pilot studies and it is possible that less clear evidence of benefit was seen because the beneficial effects of TNFα antagonism is greater in those with more severe or more corticosteroid resistant airway dysfunction. Another possibility is that the population studied by Morjaria et al contained a higher proportion of patients whose refractory symptoms were caused by non-asthma related factors. In support of this, a post hoc analysis suggested that the beneficial effects of treatment on asthma control and quality of life was more marked when the analysis was restricted to the 29 subjects not taking antidepressants. Finally, it is important to consider whether the arbitrary and sometimes illogical exclusion criteria employed in many industry sponsored multicentre studies result in loss of the patients who are most likely to respond to treatment.

1 University of Birmingham, Edgbaston, Birmingham, UK; 2 Institute for Lung Health, University Hospitals of Leicester NHS Trust, Glenfield Hospital, Leicester, UK; Correspondence to: Dr Mike A Berry, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK; m.a.berry@bham.ac.uk

Thorax July 2008 Vol 63 No 7 571
Editorial

What then can we learn from this story and how can we move the field of new drug development in refractory asthma forward? One obvious but important and often overlooked priority is to study the correct patient population and choose the right outcome measure. Thus if one is investigating an anti-eosinophil treatment, it makes sense to begin investigation in a population with severe eosinophilic airway inflammation and choose an inflammation related outcome measure such as exacerbation frequency. In contrast, if the major effects of the investigational agent are on airway smooth muscle function (as seems to be the case with anti-TNFα treatment), then a better population would be those with severe and corticosteroid resistant airway dysfunction, and better outcome measures would be symptoms, variable air-flow obstruction and airway hyperresponsiveness. Another important priority is to identify biomarkers of treatment response. In our initial study the beneficial effects of etanercept were closely related to peripheral blood mononuclear cell membrane TNFα expression. Whether this biomarker can be used to identify a population where anti-TNFα treatment can be used effectively and safely should be investigated.

At a later stage in development, or if the main effects of the investigational agent are unclear, then it is important to evaluate a sufficiently large and well characterised population for relationships between baseline demographics, potential biomarkers and treatments response to be identified. Considerable thought should be put into recruitment criteria with the emphasis more on identifying and including the at need population and less on recruiting a pure population based on arbitrary clinical and physiological criteria. If we can do this, we will learn more about the pathophysiology and heterogeneity of refractory asthma and we may have more to offer a group of patients who currently have considerable unmet needs.

Competing interests: None.


REFERENCES


Pleurodesis for malignant pleural effusion: talc, toxicity and where next?

Helen E Davies,1 Y C Gary Lee,1,2 Robert J O Davies1

Malignant pleural effusion accounts for 22% of all pleural effusions, and affects about 300 000 patients annually (UK and USA). Approximately 50% of patients with breast cancer, 25% of those with lung cancer and >90% with pleural mesothelioma develop a symptomatic malignant pleural effusion. Thoracentesis provides effective short term symptomatic relief but most large malignant pleural effusions recur, and pleurodesis is then the standard treatment. A wide range of compounds have been used as pleurodesing agents, but talc is preferred by the majority of respiratory physicians worldwide. The Medicines and Healthcare Products Regulatory Authority (MHRA) has recently completed an urgent review of the safety of talc as a pleurodesis agent for malignant effusion, reclassifying it as a medicinal product rather than medical device. This review requires that from January 2008, manufacturers must submit regulatory data if they wish their talc preparation to be used for pleurodesis. This is a milestone on the path towards improved care for malignant effusion as it heralds the first time an agent for intrapleural administration will be regulated under the systems used for biologically active drugs.

Talc is a magnesium silicate hydroxide (Mg3(Si2O5)2(OH)2) and is mined, milled and sterilised prior to clinical use, although
Antagonism of tumour necrosis factor α in refractory asthma

Mike A Berry and Ian D Pavord

Thorax 2008 63: 571-572
doi: 10.1136/thx.2007.095042

Updated information and services can be found at:
http://thorax.bmj.com/content/63/7/571.1

These include:

References
This article cites 20 articles, 5 of which you can access for free at:
http://thorax.bmj.com/content/63/7/571.1#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Asthma (1782)
- Inflammation (1020)
- Epidemiologic studies (1829)
- Health effects of tobacco use (211)
- Drugs: respiratory system (526)
- Ear, nose and throat/otolaryngology (218)
- Health education (1223)
- Obesity (public health) (197)
- Smoking (1037)
- TB and other respiratory infections (1273)
- Tobacco use (1039)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/